Sentences with phrase «in median overall survival»

The treatment resulted in a median overall survival (OS) of longer than 3 years in both arms of the trial (median OS, 38.2 months for irradiation vs 36.6 months for nonmyeloablating chemotherapy alone; hazard ratio, 1.11 [95 % CI, 0.65 — 1.91]-RRB-.

There was no statistically significant difference in median overall survival.

Not exact matches

«Patients who respond to immunotherapy tend to continue their responses for long durations, and these lengthier responses are cut off in calculations of median overall survival,» she says.

Brahmer emphasizes that the relatively small increase in median survival time with the use of the new immunotherapy drugs may be somewhat misleading in terms of overall impact of the medicines.

While there have been improvements in the current standard treatments, patients with glioblastoma (GBM), the most common and aggressive form of brain tumor, still suffer from a median survival rate of only 14.6 months and 5 - year overall survival rates of less than 10 %.

A follow - up of the 48 patients who were evaluable at a median time of 24 months indicated no statistical differences between the two groups in terms of overall or progression - free survival.

In the most recent results of the trial, treatment increased median overall survival by two months in patients treated according to protocoIn the most recent results of the trial, treatment increased median overall survival by two months in patients treated according to protocoin patients treated according to protocol.

«Similarly 71 drugs approved by the FDA from 2002 to 2014 for solid tumours have resulted in median gains in progression - free and overall survival of only 2.5 and 2.1 months, respectively,» he says adding, «Also, only 42 per cent met the American Society of Clinical Oncology Cancer Research Committee's criteria for meaningful results for patients.»

In a study presented today at a meeting of women's cancer specialists, overall survival for women who received standard chemotherapy treatment plus bevacizumab was a median five months longer than for women who received the standard chemotherapy treatment alone.

Median overall survival for woman in the chemotherapy plus bevacizumab treatment was 42.2 months, compared with 37.3 for those receiving chemotherapy alone.

The researchers found that patients capable of holding their breath over the course of treatment had a 90 percent disease - free survival, and a 96 percent overall survival, with a median reduction in radiation dose to the heart of 62 percent.

The researchers found a statistically significant difference in overall survival between the study groups, with a median of 22.8 months in the gemcitabine group compared with 20.2 months in the observation group.

In the 520 patients who had high - extent disease (whose cancer had spread to major organs and / or the bones), treatment with ADT plus docetaxel had an even greater benefit: these men had a median overall survival of 49.2 months versus 32.2 in the ADT - only group — a difference of 17 monthIn the 520 patients who had high - extent disease (whose cancer had spread to major organs and / or the bones), treatment with ADT plus docetaxel had an even greater benefit: these men had a median overall survival of 49.2 months versus 32.2 in the ADT - only group — a difference of 17 monthin the ADT - only group — a difference of 17 months.

This translated into a median overall survival of 57.6 months for men who received early chemotherapy compared with 44 months in the group given ADT as the only initial treatment — more than a year of additional life.

Those with mutations had a median overall survival of 19.1 months, compared with 9.3 months in those with EGFR mutations.

With a median follow up of 22 months, the 2 - year overall survival probability was 60.7 % in patients aged 65 years or under and 55.6 % in patients aged over 65 years (P = 0.40).

The median overall survival was 9 months in the entire chemotherapy group and 7.7 months in the erlotinib group, for a hazard ratio of 1.14 (95 % CI, 0.88 — 1.49; P = 0.313).

In RATIFY (Randomized AML Trial In FLT3 in patients less than 60 Years old, NCT00651261), for which Stone was first author, median overall survival was 74.7 months with chemotherapy plus midostaurin and 25.6 months with chemotherapy plus placebo (P = 0.009In RATIFY (Randomized AML Trial In FLT3 in patients less than 60 Years old, NCT00651261), for which Stone was first author, median overall survival was 74.7 months with chemotherapy plus midostaurin and 25.6 months with chemotherapy plus placebo (P = 0.009In FLT3 in patients less than 60 Years old, NCT00651261), for which Stone was first author, median overall survival was 74.7 months with chemotherapy plus midostaurin and 25.6 months with chemotherapy plus placebo (P = 0.009in patients less than 60 Years old, NCT00651261), for which Stone was first author, median overall survival was 74.7 months with chemotherapy plus midostaurin and 25.6 months with chemotherapy plus placebo (P = 0.009).

The median overall survival of patients in the Phase 1 resection injection study, where Toca 511 was injected into the wall of the resection cavity after removal of the tumor, exceeds historical controls across a variety of previously reported clinical trials.

The approval came on the heels of the first phase III clinical trial ever shown to improve overall survival in patients with the disease, with median overall survival of 10.1 months, versus 6.4 months in the control group.

Median overall survival, commonly referred to as median OS, is the time point at which 50 % of patients in a trial are expected to have surMedian overall survival, commonly referred to as median OS, is the time point at which 50 % of patients in a trial are expected to have surmedian OS, is the time point at which 50 % of patients in a trial are expected to have survived.

In 25 soft tissue sarcoma (STS) patients with recurrent disease treated with CMB305, median overall survival (mOS) had still not yet been reached, with an overall survival rate at 12 and 18 months of 83 % and 76 %, respectively.

While the duration of response in the velimogene aliplasmid responders was marginally longer than with DTIC / TMZ (P =.066), overall survival was shorter (median, 18.8 months [95 % CI, 16.6 — 21.3 months] vs 24.1 months [95 % CI, 17.1 — 27.9 months]; P =.491).

Fifteen dogs treated in this manner showed a median survival of 287 days and an overall survival of 956 days.